Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

LUNG CANCER

When can we be confident of surgical cure with ctDNA?

Tracking circulating tumour DNA (ctDNA) after surgery holds promise for patient management and therapeutic intervention in non-small-cell lung cancer (NSCLC). A study published by Zhang and colleagues tracks ctDNA from 261 patients with stages I–III NSCLC and suggests that the likelihood of disease relapse decreases for high-risk stage II/III patients after 18 months without ctDNA detection.

This is a preview of subscription content, access via your institution

Access options

Buy article

Get time limited or full article access on ReadCube.

$32.00

All prices are NET prices.

References

  1. Wan, J. C. M. et al. Liquid biopsies come of age: towards implementation of circulating tumour DNA. Nat. Rev. Cancer 17, 223–238 (2017).

    Article  CAS  Google Scholar 

  2. Sun, K., Jiang, P., Chan, K. C. A. & Lo, Y. M. D. Plasma DNA tissue mapping by genome-wide methylation sequencing for noninvasive prenatal, cancer, and transplantation assessments. Proc. Natl Acad. Sci. USA 112, E5503–E5512 (2015).

    Article  CAS  Google Scholar 

  3. Moding, E. J., Nabet, B. Y., Alizadeh, A. A. & Diehn, M. Detecting liquid remnants of solid tumors: circulating tumor DNA minimal residual disease. Cancer Discov. 11, 2968–2986 (2021).

    Article  CAS  Google Scholar 

  4. Abbosh, C., Birkbak, N. J. & Swanton, C. Early stage NSCLC — challenges to implementing ctDNA-based screening and MRD detection. Nat. Rev. Clin. Oncol. 15, 577–586 (2018).

    Article  CAS  Google Scholar 

  5. Zhang, J.-T. et al. Longitudinal undetectable molecular residual disease defines potentially cured population in localized non-small cell lung cancer. Cancer Discov. https://doi.org/10.1158/2159-8290.CD-21-1486 (2022).

    Article  PubMed  Google Scholar 

  6. De Mattos-Arruda, L. et al. Cerebrospinal fluid-derived circulating tumour DNA better represents the genomic alterations of brain tumours than plasma. Nat. Commun. 6, 8839 (2015).

    Article  Google Scholar 

  7. Wakelee, H. A. et al. Adjuvant chemotherapy with or without bevacizumab in patients with resected non-small-cell lung cancer (E1505): an open-label, multicentre, randomised, phase 3 trial. Lancet Oncol. 18, 1610–1623 (2017).

    Article  CAS  Google Scholar 

  8. Kurtz, D. M. et al. Enhanced detection of minimal residual disease by targeted sequencing of phased variants in circulating tumor DNA. Nat. Biotechnol. 39, 1537–1547 (2021).

    Article  CAS  Google Scholar 

  9. Wan, J. C. M. et al. ctDNA monitoring using patient-specific sequencing and integration of variant reads. Sci. Transl. Med. 12, eaaz8084 (2020).

    Article  CAS  Google Scholar 

  10. Powles, T. et al. ctDNA guiding adjuvant immunotherapy in urothelial carcinoma. Nature 595, 432–437 (2021).

    Article  CAS  Google Scholar 

Download references

Acknowledgements

M.J.-H. is a CRUK Career Establishment Awardee and has received funding from CRUK, IASLC International Lung Cancer Foundation, Lung Cancer Research Foundation, Rosetrees Trust, UKI NETs, NIHR and the NIHR UCLH Biomedical Research Centre.

Author information

Authors and Affiliations

Authors

Corresponding authors

Correspondence to Alexander Frankell or Mariam Jamal-Hanjani.

Ethics declarations

Competing interests

A.M.F. is a co-inventor on a patent application to determine methods and systems for tumour monitoring (GB2114434.0). M.J.-H. has consulted for, and is a member of the Scientific Advisory Board and Steering Committee of, Achilles Therapeutics, has received speaker honoraria from Astex Pharmaceuticals and the Oslo Cancer Cluster, and holds a patent, as co-inventor, (PCT/US2017/028013) relating to methods for lung cancer detection.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Frankell, A., Jamal-Hanjani, M. When can we be confident of surgical cure with ctDNA?. Nat Rev Clin Oncol 19, 571–572 (2022). https://doi.org/10.1038/s41571-022-00664-8

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41571-022-00664-8

Search

Quick links

Nature Briefing: Cancer

Sign up for the Nature Briefing: Cancer newsletter — what matters in cancer research, free to your inbox weekly.

Get what matters in cancer research, free to your inbox weekly. Sign up for Nature Briefing: Cancer